Step-by-step guides, research summaries, and treatment overviews β reviewed by oncology navigators and written clearly for patients, families, and caregivers.
From newly diagnosed to relapsed and refractory β we publish what patients actually need to understand their options.
What are you looking for today?
CancerFax Insights exists because cancer patients face decisions that are genuinely hard β not because of lack of will, but because the information landscape is fragmented, fast-moving, and often written for clinicians, not families.
Every insight published here is reviewed by our oncology navigation team before it goes live. We focus on the questions patients actually ask us: What is this treatment? Who qualifies? What should I prepare? What should I ask my doctor?
Use the search and filters below to find what's most relevant to your situation.
Step-by-step patient guide
Before agreeing to CAR-T therapy, families need to understand eligibility criteria, the manufacturing timeline, expected side effects, and what happens if the therapy fails. This guide walks through every question your team should be able to answer.
Browse by the topic most relevant to where you are in your cancer journey right now.
Compare options, evaluate trade-offs, understand what questions to ask before agreeing to a specific protocol.
How trial matching works, eligibility logic explained, document checklists, and what to expect during screening.
NGS testing, biomarker-based treatment matching, liquid biopsy, tumour mutation burden, and targeted therapy guides.
Cross-border treatment pathways, China and India access, visa planning, cost estimates, and logistics walk-throughs.
Practical guides for families, partners, and adult children walking alongside someone in cancer treatment.
How to prepare records, frame clinical questions, compare opinions, and navigate specialist review across borders.
Search, filter, and explore all published insights β by cancer type, treatment category, clinical trial readiness, or stage of your journey.
Search across cancer types, treatments, mutations, drugs, and trials
CancerFax Services
Cancer treatment in China costs 30β70% less than equivalent treatment in the USA or Western Europe β with internationally accredited academic cancer centres offering standard chemotherapy, targeted therapy, immunotherapy, CAR-T, proton therapy, and novel agents at prices accessible to international patients without compromising on clinical quality or GMP manufacturing standards.
Neuro-Oncology
Proton therapy for brain tumours exploits the Bragg peak to deliver tumour-ablative radiation doses with near-zero exit dose β uniquely important when treating brain tumours adjacent to brainstem, optic chiasm, cochlea, or hypothalamus. Strongest indications include paediatric brain tumours (protecting developing brain and organs), skull-base tumours (chordoma, chondrosarcoma), large meningiomas, and craniospinal irradiation for medulloblastoma. Evidence for proton over photon in GBM remains inconclusive.
Radiation Oncology
Proton therapy and BNCT are both particle-based cancer treatments, but they work by fundamentally different mechanisms. Proton therapy uses charged protons to deliver the Bragg-peak dose β stopping within the tumour with near-zero exit dose, ideal for paediatric and CNS cancers. BNCT uses tumour-targeted boron-10 and thermal neutrons to trigger an intracellular nuclear reaction β enabling tumour-cell-specific cytotoxicity at doses impossible with photon or proton beams, currently approved for recurrent head and neck cancer and glioma.
Radiation Oncology
SBRT and SRS in India cost approximately $3,000β$8,000 per course compared to $20,000β$60,000 in the United States. China offers similar cost advantages for select indications, particularly proton therapy and liver SBRT at academic centres. Both countries maintain equivalent technology standards β linear accelerators, CyberKnife, and Gamma Knife systems β at leading oncology centres.
Radiation Oncology
Advanced radiation therapy uses high-precision techniques β including IMRT, VMAT, SBRT, SRS, proton therapy, and BNCT β to deliver ablative doses to tumours while minimising harm to surrounding healthy tissue. Modern radiotherapy achieves cure in many localised cancers and effective palliation in advanced disease, with technologies now available at leading centres in India and China at significantly lower cost than in the West.
Neuro-Oncology
Advanced brain tumor treatment encompasses neurosurgical resection (including awake craniotomy and fluorescence-guided surgery), stereotactic radiosurgery (SRS/SBRT), proton therapy, BNCT, temozolomide-based chemotherapy, tumour treating fields, and emerging immunotherapies including CAR-T and neoantigen vaccines. Treatment selection depends on tumour type, WHO grade, molecular markers, and location β assessed by a specialist neuro-oncology multidisciplinary team.
Rare Cancer Treatments
First-line: nivolumab+ipilimumab (CheckMate 743) β superior OS over platinum/pemetrexed for pleural mesothelioma. 5-year survival doubled from 9% to 18%. Chinese domestic checkpoint inhibitors at lower cost. Molecular landscape: BAP1 loss (~60%), NF2 loss (~50%), low TMB. SPHIC proton therapy for localised/post-surgical disease. Peritoneal mesothel
Where are you in your cancer journey? Find insights matched to your current situation.
Understand your diagnosis, staging, reports, and first-line options before making major decisions.
Read newly-diagnosed insightsExplore second opinions, molecular testing, clinical trials, and international advanced options.
Explore next-step insightsLearn how trial matching, eligibility review, and mutation-based screening actually work.
View clinical trial insightsUnderstand how destination, treatment availability, cost, and expertise shape cross-border decisions.
Compare destinationsCurated reading lists for patients going deep into a specific treatment category or clinical question.
Cell & gene therapy
Precision oncology
Advanced radiation & local therapies
Explore insights and guides organised by the treatment modality most relevant to your case.
Find content specific to your diagnosis β from treatment overviews to clinical trial access and second opinion guidance.
Clinical trial access
CancerFax connects patients with clinical trials in China, India, and leading global centres β including phase I and II trials closed to international enrolment through standard channels.
500+
active clinical trials across China, India, and leading global centres
40+
cancer types with current advanced therapy access pathways
12+
years of patient navigation experience in cross-border oncology
Insights our navigation team recommends most often to patients starting their research.
Treatment guide Β· 8 min
02Second opinion Β· 6 min
03Precision oncology Β· 10 min
04Clinical trials Β· 7 min
05Clinical trials Β· 9 min
06Precision oncology Β· 5 min
A note from the CancerFax team
CancerFax Insights is editorially independent of the hospitals, pharmaceutical companies, and treatment centres we work with. Our navigation team writes what patients need to hear β not what any institution wants them to read.
That means we tell patients when a treatment is likely out of reach, when a clinical trial has closed, and when the evidence for a new therapy is still thin. We believe informed patients make better decisions and have better outcomes β even when the honest answer is harder to hear.
β CancerFax oncology navigation team
How our content is produced, reviewed, and how to use it effectively.
Our oncology navigators review your medical records, explain your options in plain language, and help you access the right specialists, trials, and treatment centres β wherever you are in the world.
Every navigation request is reviewed by a qualified oncology professional. We do not recommend treatments without reviewing your medical records.
